Hlavičkový papier interný - SVK - Meduni-Wien Aktuell

317. ALIAN s.r.o., Bezručova 8, Imunoalergologická ambulancia, 085 01Bardejov, MUDr. Mária Džupinová............................................................................74A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4+weekly Cetuximab versus FOLFOX4+bi-weekly Cetuximab as first-line therapy in patients with metastatic colorectal cancerKód štúdie: CECOG/CORE.1.2.002; 2006-006941-15Žiadateľ: Anny Lackovej-Zory 312038 21 MošovceSKCentrá:1. NOÚ, Klenova 1, 833 10 Bratislava, prof. MUDr. Ivan Koza2. NOÚ, Klenova 1, 833 10 Bratislava, MUDr. Jozef Šufliarsky............................................................................75A prospective randomized open-label 6-month head-to-head trial tocompare metabolic effects of paliperidone ER and olanzapine in subjects with schizophreniaKód štúdie: R076477-SCH-3020; 2006-006967-22Žiadateľ: Johnson & Johnson, s.r.o.Plynárenská 7/B824 78 BratislavaSKCentrá:1. Všeobecná nemocnica Rimavská Sobota, Kraskova 1, Psychiatrickéoddelenie,979 12 Rimavská Sobota, MUDr. Peter Korcsog2. Ružinovská poliklinika, Ružinovská 10, Psychiatrická ambulancia, 820 07Bratislava, MUDr. Peter Molčan3. Psychiatrická nemocnica Michalovce, n.o., Stráňany, Akútne psychiatrickéoddelenie 2, 071 01 Michalovce, MUDr. Monika Biačková............................................................................76Bioavailability study of two preparations containing 80mg of pentaerythrityl tetranitrate PETN 80mg tablets and Pentalong 80mg tablets after single dose to healthy volunteersKód štúdie: PT+PL/05/07; 2007-003385-17Žiadateľ: hameln rds a.s.Horná 36900 01 ModraSKCentrá:1. hameln rds a.s., Horná 36, Klinické oddelenie, 900 01 Modra, MUDr.Magdaléna Horáková............................................................................77A phase III, open-label, multicenter, single-arm, retreatment study of galiximab in combination with rituximab for subjects with relapsed, follicular non-Hodgkin´s lymphoma who previously responded on study 114-NH-301